SETBP1 overexpression and cumulative survival in AML. (A) Kaplan-Meier analyses of OS for SETBP1 in the series of age-stratified 168 patients with AML, and clinical follow-up data available. Patients older than 60 years with SETBP1 overexpression showed a poorer outcome compared with patients with no SETBP1 overexpression. (B) Kaplan-Meier analyses of OS, DFS, and EFS for SETBP1 overexpression in a series of 121 patients with AML and clinical follow-up data available who received induction therapy (note that this group of 121 patients is included in the previous series of 168 patients in panel A).